Polaryx Therapeutics, Inc. (PLYX) Stock Statistics & Valuation Metrics

Polaryx Therapeutics, Inc. has a market cap or net worth of $114.10M. The enterprise value is $106.28M.

Polaryx Therapeutics, Inc. has 47,343,296 shares outstanding. The number of shares has decreased by -2.65% in one year.

Polaryx Therapeutics, Inc.’s return on equity (ROE) is -1.97 and return on invested capital (ROIC) is -162.43%.

The current PE Ratio of Polaryx Therapeutics, Inc. is ―. Polaryx Therapeutics, Inc.’s PEG ratio is -9.82.

In the last 12 months, Polaryx Therapeutics, Inc. had revenue of 0.00 and earned -8.98M in profits. Earnings per share was -0.19.

In the last 12 months, operating cash flow was -3.09M and capital expenditures 0.00, giving a free cash flow of -3.09M billion.

Polaryx Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Polaryx Therapeutics, Inc. upcoming earnings date is ―, ―.

Polaryx Therapeutics, Inc. as a current ratio of 8.55, with Debt / Equity ratio of 0.00%

In the past 12 months, Polaryx Therapeutics, Inc. has paid 0.00 in taxes.

Polaryx Therapeutics, Inc. EV to EBITDA ratio is -183.85, with an EV/FCF ratio of -418.83.

Polaryx Therapeutics, Inc. has $5.14M in cash and marketable securities with $0.00 in debt, giving a net cash position of $5.14M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Polaryx Therapeutics, Inc. is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy